NRXBF: Raising Price Target on Trial Announcement
NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the...
204 Views
NRXBF: Company Remains Disciplined Amid Progress
NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the...
184 Views
NRXBF: Critical Year Starts with Company in Good Shape
NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the...
394 Views
NRXBF: Tests Confirm Potential for Spinal Cord Injury Recovery
NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the...
238 Views
NRXBF: US Investors Should Pay Attention
NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the...
207 Views